CTOs on the Move

Kirin Pharma USA

www.kirings.com

 
Kirin Pharma USA, Inc. is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.kirings.com
  • 9420 Athena Cir
    La Jolla, CA USA 92037
  • Phone: 858.558.1167

Executives

Name Title Contact Details

Similar Companies

Pharmadule

Pharmadule is a Bedminster, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clade Therapeutics

Clade Therapeutics is a well-funded cell therapy company developing novel cell-based medicines for the treatment of cancer and other devastating diseases. The company, located in the heart of Cambridge was recently launched by an exceptional group of academic leaders and successful bioentrepreneurs converging stem cell biology, immunology, regenerative medicine, and gene editing into the next-generation of stem cell-derived medicines.

Rhythm Pharmaceuticals

Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity.

Concentric Analgesics

Concentric Analgesics, Inc. is a private, biotechnology company focused on discovering and developing novel, non-opioid therapeutics for the management of acute and chronic pain.

Lycera

Lycera is a biopharmaceutical company that seeks to uncover new small molecule therapies for the treatment of autoimmune diseases and cancer. Our approach builds on an in-depth understanding of the orchestration of immune response in disease progression. When working correctly, the immune system can respond aggressively and with precise targeting to eliminate infectious pathogens or cancer cells. Incorrect regulation can cause the immune system to attack healthy tissue as foreign, supporting onset and progression of autoimmune disease while disruption of anti-tumor immune responses can shield cancer cells from the immune system and allow them to proliferate. Lycera is rapidly building a portfolio of selective immune modulators with mechanisms we believe will translate into improved outcomes for patients. With senior leadership and a team of scientists who represent the best of their fields, Lycera has the expertise and insight necessary to develop innovative therapies able to restore immune balance and significantly improve treatment for patients affected by these diseases around the world. Lycera product development programs are enhanced by our established global relationships with many leading chemists, scientists and clinical researchers. We are currently advancing novel small molecule compounds from distinct, yet complementary, areas of research, including immune metabolism, cell signaling and immune cell differentiation.